Scarica l'app Stockscreener
4.38
2.99%
-0.135
Dopo l'orario di chiusura:
4.38
Precedente Chiudi:
$4.515
Aprire:
$4.56
Volume 24 ore:
44,093
Relative Volume:
0.72
Capitalizzazione di mercato:
$75.24M
Reddito:
$37.16M
Utile/perdita netta:
$-17.83M
Rapporto P/E:
-4.236
EPS:
-1.034
Flusso di cassa netto:
$-14.22M
1 W Prestazione:
+0.23%
1M Prestazione:
-18.74%
6M Prestazione:
-19.93%
1 anno Prestazione:
-3.52%
Intervallo 1D:
$4.37
$4.8434
Intervallo di 1 settimana:
$4.32
$5.04
Portata 52W:
$3.28
$9.8212
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Nome
Verrica Pharmaceuticals Inc
Settore
Industria
Telefono
484-453-3300
Indirizzo
44 WEST GAY STREET, WEST CHESTER, PA
Compare VRCA vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
4.38 | 75.07M | 37.16M | -17.83M | -14.22M | -1.034 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-06 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-07-25 | Aggiornamento | Needham | Hold → Buy |
| 2023-03-22 | Iniziato | Jefferies | Buy |
| 2023-02-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-12-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-06-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-24 | Iniziato | Northland Capital | Outperform |
| 2020-03-24 | Iniziato | Needham | Buy |
| 2019-02-21 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Verrica Pharmaceuticals Inc Borsa (VRCA) Ultime notizie
Debt to assets ratio of Verrica Pharmaceuticals Inc. – HAN:1NE0 - TradingView
An estimated 60.1% of patients cleared a contagious skin disease by day 84, versus 19.9% in the comparison group. - Stock Titan
Verrica Pharmaceuticals Inc. Earnings and Revenue – HAN:1NE0 - TradingView
Verrica Pharmaceuticals Inc. Revenue Breakdown – HAN:1NE0 - TradingView
Verrica Pharmaceuticals stock trades at USD 4.10 - AD HOC NEWS
Verrica Pharmaceuticals stock holds steady as investors watch latest clinical and earnings signals - AD HOC NEWS
VRCA News | VERRICA PHARMACEUTICALS INC (NASDAQ:VRCA) - ChartMill
Verrica Pharmaceuticals stock holds steady as investors look to lead product progress - AD HOC NEWS
VRCA: Phase III programs for common warts and BCC advance rapidly, with strong efficacy and global expansion - TradingView
Verrica Pharmaceuticals at H.C. Wainwright conference: growth and pipeline By Investing.com - Investing.com Canada
Verrica Puts Investor Focus on Dermatology Pipeline - MyChesCo
Net current asset value per share of Verrica Pharmaceuticals Inc. – HAM:1NE0 - TradingView
Number of shareholders of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA - tradingview.com
Number of shareholders of Verrica Pharmaceuticals Inc. – HAM:1NE0 - TradingView
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences - marketscreener.com
Verrica Pharmaceuticals Inc. Balance Sheet – HAM:1NE0 - TradingView
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
Verrica Pharmaceuticals Stock Price Forecast. Should You Buy VRCA? - StockInvest.us
Verrica Pharmaceuticals Inc. (VRCA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Verrica Advances Wart Drug Expansion as Phase 3 Trial Fills - MyChesCo
Verrica Pharmaceuticals (VRCA) Drops 4% to $5.46 as Support Level Comes into FocusPercent Above MA - dars.gov.et
Breakout Bulletin: August 24-August 28 - Dermatology Times
Verrica completes enrolment in Phase III trial of Ycanth - Clinical Trials Arena
Technical Analysis on One NASDAQ- Listed Pharmaceuticals Stock: VRCA - Kalkine
Verrica Completes Enrollment in Phase 3 YCANTH Common Warts Trial - Dermatology Times
VRCA Looks 46.0% Undervalued on GF Value™ Despite Speculative Ri - GuruFocus
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027 - Yahoo Finance
Verrica (VRCA) Results Versus Estimates: The Bottom-Line Figure Trails Its Comparison in the Current Update; Share Move: Shares Move 1.04% Up at the CloseEarnings Miss Streak - dars.gov.et
Verrica (VRCA) Financial Results: EPS Comes in Below Forecast in the Reported Period; Price Move: Shares Fall 0.82% for the Current SessionGuidance Revision Trend - vinanet.vn
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Verrica (VRCA) Financial Results: EPS Misses Its Estimate in Latest Trading; Trading-Day Reaction: Shares Move 4.29% Lower on the DayReturn On Capital - vinanet.vn
Verrica Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
VRCA Looks 50.3% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Purchases 4,200 Shares of Stock - MarketBeat
Verrica Pharmaceuticals (NASDAQ:VRCA) CEO Jayson Rieger Acquires 5,000 Shares - MarketBeat
Verrica (NASDAQ: VRCA) interim CFO adds 5,000 shares in open-market buy - Stock Titan
Verrica (NASDAQ: VRCA) CEO buys 25,000 shares in August - Stock Titan
Verrica (VRCA) Q2 2026 Earnings Call Transcript - AOL.com
Verrica Pharmaceuticals Inc (VRCA) (Q2 2026) Earnings Call Highl - GuruFocus
Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Verrica Revenue Falls Despite Record YCANTH Demand - MyChesCo
Verrica Pharmaceuticals (VRCA) Holds Steady at $5.08 as Range Trade PersistsLinear Regression - dars.gov.et
Verrica Pharmaceuticals Inc. R (1NE0.DU) balance sheet - Yahoo Finance UK
Q2 2026 Verrica Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Verrica Pharmaceuticals Inc. R (1NE0.DU) stock price, news, quote and history - Yahoo Finance UK
Verrica Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Verrica secures $27.5 million credit facility from chairman By Investing.com - Investing.com South Africa
Needham Maintains Verrica Pharmaceuticals(VRCA.US) With Hold Rating - Moomoo
Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Earnings Results - MarketBeat
Earnings call transcript: Verrica Q2 2026 loss widens as YCANTH sales rise - Investing.com
Verrica Pharmaceuticals earnings missed by $0.08, revenue topped estimates - Investing.com Canada
Verrica Pharmaceuticals Inc Azioni (VRCA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Verrica Pharmaceuticals Inc Azioni (VRCA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Rieger Jayson | CEO and President |
Aug 14 '26 |
Buy |
5.06 |
20,000 |
101,200 |
202,593 |
| Rieger Jayson | CEO and President |
Aug 17 '26 |
Buy |
4.91 |
5,000 |
24,550 |
207,593 |
| Rosenberg Noah L. | CMO |
Aug 17 '26 |
Buy |
4.91 |
4,200 |
20,622 |
6,557 |
| Rosenberg Noah L. | CMO |
Aug 18 '26 |
Buy |
4.92 |
2,030 |
9,988 |
8,587 |
| Kirby John J. | Interim CFO |
Aug 18 '26 |
Buy |
4.93 |
5,000 |
24,650 |
23,962 |
| Rosenberg Noah L. | CMO |
Nov 25 '25 |
Buy |
4.24 |
2,357 |
10,000 |
2,357 |
| Kirby John J. | Interim CFO |
Nov 25 '25 |
Buy |
4.24 |
3,536 |
15,001 |
8,962 |
| Zawitz David | Chief Operating Officer |
Nov 25 '25 |
Buy |
4.24 |
10,000 |
42,425 |
21,000 |
| Rieger Jayson | CEO and President |
Nov 25 '25 |
Buy |
4.24 |
94,311 |
400,114 |
182,593 |
| Manning Paul B | Director |
Nov 25 '25 |
Buy |
4.24 |
2,750,762 |
11,670,108 |
3,348,372 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):